Thrombolytic therapy in acute ischemic stroke with streptokinase
AIM AND METHODS: In an open, observational study, 40 consecutive ischemic stroke patients eligible for thrombolytic therapy using the combined ECASS/NINDS inclusion criteria have been treated intravenously with 1.5 M units of streptokinase. The therapeutic window was 3 hours or shorter.
RESULTS: The safety analysis documented a low rate (5%) of intracerebral hemorrhages, and an additional 13% rate of hemorrhagic transformation of the initial infarction. Two patients died due to intracerebral bleeding. The efficacy of the SK thrombolysis was significant in 53% of the patients (the mean of the improvement on the NIH stroke scale was 15 points), while an other 42% of the patients achieved only the mean of 4 points improvement on their NIHSS score.
DISCUSSION: These results are of the same magnitude, as those documented in the NINDS trial with rt-PA. Time window rather than the thrombolytic agent itself seems to be the decisive factor for successful thrombolysis.
CONCLUSION: The good safety profile of SK in acute stroke using the ECASS/NINDS criteria, and the cost-effectiveness of the drug underline the necessity of a new SK trial with the recently accepted inclusion and exclusion criteria.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 143(2002), 23 vom: 09. Juni, Seite 1415-21 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Akut ischaemiás stroke thrombolyticus kezelése sztreptokinázzal |
|---|
| Beteiligte Personen: |
Szegedi, Norbert [VerfasserIn] |
|---|
| Themen: |
EC 3.4.- |
|---|
| Anmerkungen: |
Date Completed 16.08.2002 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM119982048 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM119982048 | ||
| 003 | DE-627 | ||
| 005 | 20231222185921.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0400.xml |
| 035 | |a (DE-627)NLM119982048 | ||
| 035 | |a (NLM)12132328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Szegedi, Norbert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thrombolytic therapy in acute ischemic stroke with streptokinase |
| 246 | 3 | 3 | |a Akut ischaemiás stroke thrombolyticus kezelése sztreptokinázzal |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2002 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM AND METHODS: In an open, observational study, 40 consecutive ischemic stroke patients eligible for thrombolytic therapy using the combined ECASS/NINDS inclusion criteria have been treated intravenously with 1.5 M units of streptokinase. The therapeutic window was 3 hours or shorter | ||
| 520 | |a RESULTS: The safety analysis documented a low rate (5%) of intracerebral hemorrhages, and an additional 13% rate of hemorrhagic transformation of the initial infarction. Two patients died due to intracerebral bleeding. The efficacy of the SK thrombolysis was significant in 53% of the patients (the mean of the improvement on the NIH stroke scale was 15 points), while an other 42% of the patients achieved only the mean of 4 points improvement on their NIHSS score | ||
| 520 | |a DISCUSSION: These results are of the same magnitude, as those documented in the NINDS trial with rt-PA. Time window rather than the thrombolytic agent itself seems to be the decisive factor for successful thrombolysis | ||
| 520 | |a CONCLUSION: The good safety profile of SK in acute stroke using the ECASS/NINDS criteria, and the cost-effectiveness of the drug underline the necessity of a new SK trial with the recently accepted inclusion and exclusion criteria | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Streptokinase |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Plasminogen Activators |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 700 | 1 | |a Kakuk, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Kenéz, Júlia |e verfasserin |4 aut | |
| 700 | 1 | |a May, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Ováry, Csaba |e verfasserin |4 aut | |
| 700 | 1 | |a Ricsóy, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Skopál, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Varga, Dániel |e verfasserin |4 aut | |
| 700 | 1 | |a Harsányi, Adám |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Zoltán |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 143(2002), 23 vom: 09. Juni, Seite 1415-21 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2002 |g number:23 |g day:09 |g month:06 |g pages:1415-21 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2002 |e 23 |b 09 |c 06 |h 1415-21 | ||